比较奥氮平与喹硫平对阿尔茨海默病患者睡眠呼吸功能的影响(1)
[摘要] 目的 分析比較阿尔茨海默病患者，使用奥氮平和喹硫平后对患者睡眠呼吸功能的影响。方法 方便选取该院2014年1月—2015年12月收治的阿尔茨海默病患者80例，随机分成两组，每组40例。第一组使用奥氮平进行治疗，治疗疗程为8周，第二组使用喹硫平进行治疗，治疗疗程为8周。在阿尔茨海默病患者治疗前和治疗后进行多导睡眠图检查，对阿尔茨海默病患者的睡眠呼吸功能进行检测。检测阿尔茨海默病患者的平均血氧饱和度、最低血氧饱和度、血氧饱和度<90%时间占总监测时间的比例以及患者呼吸暂停低通气指数，对比奥氮平和喹硫平对阿尔茨海默病患者睡眠呼吸功能的影响。 结果 第一组患者使用奥氮平治疗后，血氧饱和度<90%时间占总监测时间的比例为(13.3±4.8)%，对比治疗前有明显增高(9.1±4.2)%，并且高于第二组使用喹硫平的患者(9.8±4.5)%。第一组的呼吸暂停低通气指数也有增高(13.5±5.1)次/h，并且明显高于第二组的呼吸暂停低通气指数(9.1±4.3)次/h。第一组的最低血氧饱和度(78.1±8.1)%和平均血氧饱和度(91.2±4.5)%有所降低，并且明显低于第二组患者(83.2±9.4)%、(95.0±3.8)%。两组对比差异有统计学意义(P<0.05)。阿尔茨海默病患者在治疗前，阻塞性睡眠呼吸暂停低通气综合征的发病率是27.8%，患者治疗后，第一组出现这种症状的比例比第二组高，两组患者的阿尔茨海默病病理行为量表有明显的降低，简易精神状态检查没有明显变化。结论 阿尔茨海默病患者使用奥氮平可能对睡眠呼吸功能有不良影响，使用喹硫平影响不明显。
[关键词] 奥氮平；喹硫平；阿尔茨海默病；睡眠呼吸功能
[中图分类号] R741 [文献标识码] A [文章编号] 1674-0742(2017)01(c)-0126-03
Quetiapine on the Sleep Respiratory Function of Patients with Alzheimer Disease
WU Nan
Mental and Health Center， Zibo， Shandong Province， 255000 China
[Abstract] Objective To analyze the effect of Olanzapine and quetiapine on the sleep respiratory function of patients with Alzheimer disease. Methods 80 cases of patients with Alzheimer disease admitted and treated in our hospital from January 2014 to December 2015 were convenient selected and randomly divided into two groups with 40 cases in each， the first group were treated with Olanzapine for eight weeks， while the second group were treated with quetiapine for eight weeks， and the patients with Alzheimer disease before and after treatment were examined by the polysomnogram， and the sleep respiratory function of patients with Alzheimer disease was tested， and the average oxygen saturation of blood， lowest oxygen saturation of blood， ratio of time of oxygen saturation of blood less than 90% in the total monitoring time and apnea hypoventilation index of patients were tested， and the effect of Olanzapine and quetiapine on the sleep respiratory function of patients with Alzheimer disease was compared. Results After treatment， the ratio of time of oxygen saturation of blood less than 90% in the total monitoring time in the first group was higher than that in the second group[(13.3±4.8)% vs (9.8±4.5)%]， and the apnea hypoventilation index of patients in the first group was obviously higher than that in the second group(13.5±5.1)times/h vs(9.1±4.3)times/h ， the lowest oxygen saturation of blood and average oxygen saturation of blood in the first group were obviously lower than those in the second group， [(78.1±8.1)%， (91.2±4.5)% vs (83.2±9.4)%， (95.0±3.8)%]，and the differences between the two groups had statistical significance by comparison(P<0.05)， before treatment， the incidence rate of obstructive sleep apnea hypopnea syndrome was 27.8%， after treatment， the ratio of the symptom was higher than that in the second group， and the Alzheimer pathological behavior scale of the two groups decreased obviously， and the Mini-Mental State Examination had no obvious change. Conclusion The use of Olanzapine for patients with Alzheimer disease may have no adverse effect on the sleep respiratory function and the effect of quetiapine is not obvious., http://www.100md.com(吴楠)
[关键词] 奥氮平；喹硫平；阿尔茨海默病；睡眠呼吸功能
[中图分类号] R741 [文献标识码] A [文章编号] 1674-0742(2017)01(c)-0126-03
Quetiapine on the Sleep Respiratory Function of Patients with Alzheimer Disease
WU Nan
Mental and Health Center， Zibo， Shandong Province， 255000 China
[Abstract] Objective To analyze the effect of Olanzapine and quetiapine on the sleep respiratory function of patients with Alzheimer disease. Methods 80 cases of patients with Alzheimer disease admitted and treated in our hospital from January 2014 to December 2015 were convenient selected and randomly divided into two groups with 40 cases in each， the first group were treated with Olanzapine for eight weeks， while the second group were treated with quetiapine for eight weeks， and the patients with Alzheimer disease before and after treatment were examined by the polysomnogram， and the sleep respiratory function of patients with Alzheimer disease was tested， and the average oxygen saturation of blood， lowest oxygen saturation of blood， ratio of time of oxygen saturation of blood less than 90% in the total monitoring time and apnea hypoventilation index of patients were tested， and the effect of Olanzapine and quetiapine on the sleep respiratory function of patients with Alzheimer disease was compared. Results After treatment， the ratio of time of oxygen saturation of blood less than 90% in the total monitoring time in the first group was higher than that in the second group[(13.3±4.8)% vs (9.8±4.5)%]， and the apnea hypoventilation index of patients in the first group was obviously higher than that in the second group(13.5±5.1)times/h vs(9.1±4.3)times/h ， the lowest oxygen saturation of blood and average oxygen saturation of blood in the first group were obviously lower than those in the second group， [(78.1±8.1)%， (91.2±4.5)% vs (83.2±9.4)%， (95.0±3.8)%]，and the differences between the two groups had statistical significance by comparison(P<0.05)， before treatment， the incidence rate of obstructive sleep apnea hypopnea syndrome was 27.8%， after treatment， the ratio of the symptom was higher than that in the second group， and the Alzheimer pathological behavior scale of the two groups decreased obviously， and the Mini-Mental State Examination had no obvious change. Conclusion The use of Olanzapine for patients with Alzheimer disease may have no adverse effect on the sleep respiratory function and the effect of quetiapine is not obvious., http://www.100md.com(吴楠)